Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Sarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Carcinoma, Renal Cell 3Wilms Tumor 2Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Astrocytoma 2

Interventions

pazopanib 1ixabepilone 1Thalidomide 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Corpus Sarcoma × ixabepilone × Clear all
NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡